Viewing Study NCT01223235

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:09 PM
Ignite Modification Date: 2026-02-03 @ 2:18 PM
Study NCT ID: NCT01223235
Status: COMPLETED
Last Update Posted: 2018-06-12
First Post: 2010-10-14
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fallopian Tubes Cancer View
None Ovarian Cancer View
None Peritoneal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None FALLOPIAN TUBE View
None OVARY View
None PERITONEUM View
None BEVACIZUMAB (AVASTIN) View
None GLOBO H-KLH CONJUGATE View
None MUC-1 KLH View
None OPT-821 View
None TF (C) - KLH View
None TN(C)-KLH View
None 10-099 View